Clinical Trials Directory

Trials / Completed

CompletedNCT03862716

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira (REMIT IDegLira): A Randomized Controlled Trial

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
159 (actual)
Sponsor
Population Health Research Institute · Academic / Other
Sex
All
Age
30 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising IDegLira, metformin, and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.

Detailed description

This is a multicentre, open-label, randomized controlled trial in 160 patients with recently-diagnosed T2DM. Participants will be randomized to 2 treatment groups: (a) a 16-week course of treatment with IDegLira, metformin and lifestyle therapy, and (b) standard diabetes therapy, and followed for a total of 68 weeks (1 year and 4 months). In all participants with HbA1C\<7.3% at the 16 week visit, glucose-lowering medications will be discontinued and participants will be encouraged to continue with lifestyle modifications and regular glucose monitoring. Participants with HbA1C ≥ 7.3% at this visit or who experience hyperglycemia relapse after stopping drugs will receive standard glycemic management as informed by the current Canadian Diabetes Association clinical practice guidelines.

Conditions

Interventions

TypeNameDescription
DRUGIDegLiraDose is titrated to achieve fasting normoglycemia
DRUGinsulin degludecIn those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.
DRUGMetforminDose is titrated to 2000 mg per day or maximal tolerated dose
BEHAVIORALLifestyle TherapyLifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving

Timeline

Start date
2019-04-23
Primary completion
2022-06-15
Completion
2023-07-31
First posted
2019-03-05
Last updated
2023-10-25

Locations

8 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT03862716. Inclusion in this directory is not an endorsement.